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Background: The TAM-receptor tyrosine kinase family, Tyro3, Axl and Mer are key to apoptotic cell clearance. Reduced
phagocytic clearance in systemic lupus erythematosus (SLE) leads to prolonged exposure of nuclear autoantigen to the
immune system. Here we measure the levels of TAM receptors and the phagocytic capacity of monocytes and
macrophages in juvenile-onset SLE (JSLE).
Method: Mer protein was measured on monocytes from JSLE, healthy control and JIA patients. JSLE, healthy control
and JIA patients’ plasma were analysed for soluble Mer (sMer), soluble Tyro3 (sTyro) and soluble Axl (sAxl). A
phagocytosis assay measured the effect of JSLE serum on phagocytic potential of JSLE and control monocytes to
engulf E. Coli bacteria and healthy macrophages to engulf apoptotic neutrophils.
Results: Mer receptor expression was significantly decreased on JSLE monocytes compared to healthy controls. Plasma
sMer, sTyro and sAxl were significantly increased in JSLE patients compared to controls (p < 0.05). Adult healthy control
macrophages had significantly decreased phagocytosis of E. Coli and apoptotic neutrophils in the presence of 10% JSLE
serum compared to control serum (p < 0.05).
Conclusion: JSLE patients have a decreased phagocytosis due to both serum and cell-derived factors. Significantly
increased levels of sMer, sTyro3 and sAxl may be important factors contributing to the deficit in phagocytosis ability.
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Phagocytosis is the engulfment and internalisation by
phagocytes of particulate targets including microorgan-
isms, apoptotic cells and environmental debris. Charac-
teristically, phagocytic removal of apoptotic cells is a
non-inflammatory process, and does not induce an im-
mune response. Juvenile-onset SLE (JSLE) (diagnosed
before the age of 17) is generally a more severe disease
associated with greater organ damage compared to
adult-onset SLE [1]. The etiology of JSLE remains uncer-
tain [2] but is serologically characterised by autoanti-
bodies directed against nuclear autoantigens [3]. It is
hypothesised that impaired phagocytosis results in pro-
longed exposure of apoptotic cells to the immune system* Correspondence: m.w.beresford@liverpool.ac.uk
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unless otherwise stated.leading to production of autoantibodies directed against
intracellular nuclear components. Our group has previ-
ously demonstrated significantly greater, dysregulated
neutrophil apoptosis in JSLE patients compared to
healthy controls [4] which have increased surface ex-
pression of nuclear antigens [5].
Monocytes and macrophages, two important phago-
cytes, use surface receptors to perform phagocytic uptake
of apoptotic cells. The TAM-receptor tyrosine kinase fam-
ily consists of three phagocytic receptors: Tyro3, Axl and
Mer [6] and are key to apoptotic cell clearance [7] but not
required for phagocytosis of bacteria [8]. They recognise
the apoptotic cell surface membrane marker phosphatidyl-
serine through two bridging molecules, protein S (ProS)
and “a product of growth arrest-specific gene 6” (Gas6).
Mer can also act in an anti-inflammatory manner being
primarily expressed on anti-inflammatory M2c macro-
phages [9]. TAM receptors broadly act through inhibitionral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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receptor cascades [10]. Gas6 inhibits Tumor Necrosis
Factor alpha (TNFα) and Interleukin 6 (IL-6) secretion
by Lipopolysaccharide (LPS) stimulated monocytes and
macrophages through Mer activation [11]. Cleavage of
the extra-cellular membrane bound Mer to form soluble
Mer (sMer) occurs via the metalloproteinase A disinte-
grin and metalloproteinase protein 17 (ADAM17) also
known as TACE (tumour necrosis factor-α-converting
enzyme) [12]. Mer cleavage leads to receptor inactivation
reducing the number of membrane-bound receptors. sMer
inhibits macrophage phagocytosis by acting as a decoy-
receptor [13] and preventing the anti-inflammatory proper-
ties of Gas6-mediated stimulation of membrane-bound
Mer. Stimulating monocytes or macrophages with LPS
and phorbol-12-myristate-13-acetate (PMA) induces
Mer cleavage [13]. Intrinsic monocyte and macrophage
phagocyte dysfunction [14] and lupus serum itself may
both contribute to impaired phagocytosis in adult onset
SLE [15,16]. The aim of this study was to investigate
the role of Mer and the three soluble phagocytosis re-




This study was part of the UK JSLE Cohort Study [17] and
approved by the Liverpool Paediatric Research Ethics
Committee. Written informed assent/consent was ob-
tained from all participating patients/parents. All JSLE
patients fulfilled the revised American College of
Rheumatology (ACR) criteria for SLE [18] before the
age of 17 years. Paediatric non-inflammatory controls
were children without inter-current infection or inflam-
matory musculoskeletal conditions undergoing elective
surgery. All juvenile idiopathic arthritis (JIA) patients
met International League of Arthritis and Rheumatism
(ILAR) classification criteria [19], serving as an auto-
immune inflammatory control. All patients were re-
cruited from outpatient clinics and inpatient wards at
Alder Hey Children’s National Health Service (NHS)
Foundation Trust. All study samples were anonymized
following collection.
Monocyte separation and macrophage preparation
Immediately following phlebotomy, samples were trans-
ferred directly to the laboratory for processing. For
monocytes preparation, peripheral blood mononuclear
cells (PBMCs) were isolated from fresh heparinised
blood within 1 hour of collection by 1-step centrifuga-
tion through Polymorph Prep (Axis-shield, Kimbolton,
UK) following manufacturer’s instructions. Contaminating
erythrocytes were removed by hypertonic lysis. CD14+
cells were separated from PBMCs by magnetic selectionusing CD14+ microbeads (Miltenyi Biotech) according to
the manufacturer’s instructions. The purity of these cells
were assessed and was consistently >95%. For macrophage
preparation, the monocytes were differentiated by cultur-
ing with 50 ng/ml Macrophage Colony Stimulating Factor
(M-CSF) (Miltenyi Biotech) in RPMI-1640 media contain-
ing 10% fetal calf serum (FCS) and 1% penicillin/strepto-
mycin (all from Sigma-Aldrich, Poole, UK) for 6 days at
37°C in an atmosphere containing 5% CO2. After this dur-
ation macrophages were removed from culture plates
using cell dissociation solution (Sigma). The macrophages
were washed in phosphate buffered saline (PBS; Sigma)
and counted before being used for RNA extraction or the
phagocytosis assay.
Phagocytosis assay
A pH sensitive dye pHrodo (Invitrogen) that obtains a
red fluorescence under exposure to acidic pH was used
for analysing phagocytosis. Phagolysosomes bear an
acidic pH, therefore material fully phagocytosed can be
quantified.
Monocytes/macrophages from adult healthy control or
patients were isolated by the methods outlined and
washed twice in Hanks Balanced Salt Solution (HBSS;
GIBCO pH 7.4). For the phagocytosis assay, the mono-
cytes/macrophages were incubated with E. Coli pre-
stained with pHrodo in the presence of 10% JSLE, JIA or
control serum for 30 minutes at 37°C. As a negative
control an identical tube of cells was incubated at 4°C
for 30 minutes. After this duration the cells were washed
three times and resuspended in HBSS before being ana-
lysed on the flow cytometer. The percentage of phagocyt-
osis taking place at 4°C was deduced from the phagocytosis
percentage at 37°C to remove any background fluorescence
or auto-fluorescence.
Phagocytosis assay of apoptotic neutrophils using
confocal microscopy
Neutrophils were isolated from adult healthy controls as
previously described [4] and left in 5% CO2 at 37°C
overnight to undergo apoptosis. Apoptosis was measured
using annexin V as previously described [4], in brief neu-
trophils were removed from culture and re-suspended in
HBSS (Invitrogen). Annexin V-FITC (Sigma-Aldrich) was
added at a 1/100 dilution and cells were incubated at 4°C
for 15 min, cells were pelleted at 400 x g and re-suspended
in HBSS before analysis by flow cytometry using a FC500
MPL flow cytometer. Apoptotic neutrophils were stained
with pHrodo dye following manufacturer instructions (Life
Technologies). Monocytes from adult healthy controls were
seeded onto coverslips and differentiated into macro-
phages as outlined. pHrodo stained apoptotic neutro-
phils were incubated with the macrophages in the
presence of 10% JSLE, JIA or control serum for 2 hrs.
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HBSS. To aid orientation, DNA was stained with 1 mg/ml
2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochlor-
ide (DAPI) (Sigma-Aldrich), for 5 minutes. Cells were
washed with 1xTBS and viewed with a confocal laser-
scanning microscope (LeicaDM2500). Images were taken
with a 40 x objective and detection settings were kept
constant between conditions to compare fluorescence
intensities.
Flow cytometry staining for Mer and ADAM17
Following isolation, cells were washed in HBSS and
blocked in mouse serum for 15 minutes at room
temperature before being incubated with either Fluorescein-
conjugated Mer (R +D), Fluorescein-conjugated ADAM17
(R + D) or isotype control for 30 minutes in the
dark at 4°C. Cells were washed and resuspended in
HBSS before being immediately analysed on a flow
cytometer.
RNA and RT-PCR analysis
RNA was extracted from CD14+ monocytes and macro-
phage cells using the RNeasy Mini kit (Qiagen Inc.,
Canada). The concentration and purity of RNA was con-
firmed by the relative absorbance at 260 nm and meas-
uring the 260/280 nm ratio using a ND-1000 NanoDrop
spectrometer (Thermo Scientific). First strand cDNA
synthesis was initiated from 100 ng total RNA using ran-
dom hexamers (Promega, Madison, WI, USA) and avian
myeloblastosis virus reverse transcriptase (Promega) using
conditions described by the manufacturer in a final volume
of 25 μl. The primers used were as follows: β2M forward
5’-TGCCTGCCGTGTGAACCATGT-3’; β2M reverse 5’-
TGCGGCATCTTCAAACCTCCATGA-3’; MER forward
5’-CCGCCTGAGCCCGTCAACATT-3’; MER reverse 5’-
CTCCGTCAGGCTGGAACAGT-3’. All quantitative real-
time PCR took place using the SYBR green fluorescence
method with SYBR green qPCR mastermix (Stratagen, La
Jolla, CA, USA) as specified by the manufacturer. The
real-time PCR reactions took place in triplicate on a
MX4000® Multiplex Quantitative QPCR system (Strata-
gene) using standard thermal cycling conditions. Non-
template controls were prepared by replacing the cDNA
fraction of the PCR reaction with an equivalent volume of
nuclease free water (Promega). Quantification of tran-
scripts took place using the relative standard curve
method. mRNA expression for each gene was normalised
to the internal standard β2M.
Measurement of sMer, sTyro3 and sAxl
Soluble receptor concentrations in patient plasma sam-
ples were measured using manufactured enzyme-linked
immunosorbant assay (ELISA) kits for human total Mer,
Tyro3 or Axl (R + D Systems) following manufacturer’sinstructions. Samples were diluted 1 in 5 for Mer and
Tyro3 and were diluted 1 in 15 for Axl. The ELISA kit
was validated using a spike and recovery assay prior to
use (mean recovery 113%).
ADAM17 activity assay
Monocytes were isolated from JSLE, healthy control and
JIA patients and were lysed in Cytobuster reagent (Merk
Milipore) according to the manufacturer’s instructions at
a concentration of 1 × 106 monocytes per 150 μl of re-
agent. Samples were stored at -20°C until required.
ADAM17 activity was analysed in neat samples using
InnoZyme™ TACE Activity Kit (Calbiochem) according
to the manufacturer’s instructions and the assay was
analysed on a fluorescence plate reader.
Statistical analysis
All data are presented as the mean ± SEM. Comparisons
between patients were made using the Mann-Whitney
test. All analyses were performed using GraphPad Prism 4




Table 1 presents demographic data of the patient groups
included in the analysis of the plasma levels of sMer,
sTyro3 and sAxl including biomarkers of disease activity
and medication at time of sample collection.
Significantly reduced phagocytosis of E. coli in the
presence of JSLE serum
SLE serum has been shown to contribute to impaired
phagocytosis in adult onset SLE [15,16]. In this study,
adult healthy control macrophages incubated with 10%
JSLE serum (n = 8) had a significantly lower percentage
phagocytosis of E. Coli measured by flow cytometry
compared to macrophages incubated with control serum
(n = 7; p = 0.021) (Figure 1A). However there was no sig-
nificant difference in phagocytosis of E. Coli by adult
healthy control monocytes incubated in 10% JSLE (n = 11)
compared to JIA (n = 8) and healthy control (n = 11)
serum (p > 0.05; Figure 1B).
Control serum can restore phagocytic potential of JSLE
monocytes
Monocyte cells isolated from JSLE (n = 5; Figure 1C) or
healthy control patients (n = 5; Figure 1D) were incu-
bated with E coli in the presence of donor matched
serum or JSLE, JIA or healthy control serum. The JSLE
monocytes incubated in donor-matched serum had a
significantly decreased amount of E coli phagocytosis,
which could be reversed by incubating the same JSLE
monocytes in control (p = 0.0028) or JIA (p = 0.002)
Table 1 sMer, sTyro3 and sAxl ELISA demographic data
Demographics sMer measurement in JSLE
patients (n = 15)
sTyro3 measurement in JSLE
patients (n = 30)
sAxl measurement in JSLE
patients (n = 14)
Number (%) female 9 (60%) 22 (73%) 11 (79%)
Ethnicity, number
White British 10 21 10
Asian 5 9 4
Age at sampling, mean (range) years 14.2 (3.5 – 18.7) 14.0 (7.5 - 17.9) 15.5 (10.7-19.4)
Disease duration, mean (range) years 3.0 (0.4 – 9.1) 3.1 (0 – 11.8) 3.5 (0 – 11.5)
Biomarker/disease activity parameter, mean
(range)
ESR, mm/hour (normal 2-8 mm/hour) 15 (1 – 60) 18.5 (<1 – 108) 12.6 (1-50)
CRP, mg/litre (normal 0-8 mg/litre) 11.2 (<4 – 78.9) 6.4 (<4 – 43.3) 4.1 (4-5.6)
C3, gm/litre (normal 1.1 – 1.9) 0.8 (0.5 – 1.4) 1.3 (0.6 – 10.9) 1.1 (0.4 – 1.4)
C4, gm/litre (normal 0.19 – 0.56) 0.14 (0.09 – 0.34) 0.15 (0.08 – 0.46) 0.2 (0.05 – 0.5)
Anti-dsDNA titre, IU/ml (normal <7) 3.1 (14 – 32) 4.9 (0 – 58) 424 (0 – 5408)
C-HAQ score, 0-3, mean (range) 0.27 (0.13 – 2.38) 0.44 (0 – 2.38) 0.64 (0 – 2.25)
Physician’s global assessment of disease activity
by VAS, mean (range) mm
19 (5 – 80) 19.4 (0 – 85) 25 (0 – 70)
BILAG-2004
Number with grade A or grade B 5 11 6
Score, mean (range) 2.6 (1 – 15) 2.9 (0 – 19) 3.8 (0 – 9)
Current medications, number of patients
Hydroxychloroquine 13 19 10
Methotrexate 0 3 0
Azathioprine 3 4 3
Mycophenolate mofetil 8 13 7
Prednisolone 11 13 6
Prednisolone dosage, mean (range) mg/day 7.4 (1 – 30) 14.4 (3 – 40) 15.8 (2 – 60)
Rituximab 1 0 1
Infliximab 1 2 2
This table presents the demographics, disease and therapeutic profiles, and clinical biomarker results of the JSLE group. Any JSLE patients with a BILAG score of A
or B for any organ system at the time of sample collection were considered to have active disease.
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trol donor monocytes had a higher level of E coli phago-
cytosis which was significantly reduced when the same
monocytes cells were incubated in JSLE serum (p = 0.018)
(Table 2B and Figure 1D).
Reduced phagocytosis of apoptotic neutrophils in the
presence of JSLE serum compared to controls
The effect of JSLE serum on phagocytosis of apoptotic
cells was also investigated. Neutrophils that had under-
gone >60% apoptosis (measured using annexin v staining
and flow cytometry) were stained with pHrodo and co-
incubated with adult control macrophages with no
serum or 10% JSLE, JIA or control serum (n = 7 sera).
As expected, those macrophages without a serum
enriched environment displayed the lowest level ofphagocytosis (Figure 2A). Macrophages incubated with
10% JSLE serum displayed significantly lower phagocyt-
osis of apoptotic neutrophils as measured by confocal
microscopy, when compared to macrophages incubated
with 10% paediatric control serum (Figure 2A and B).
The percentage of phagocytosis following incubation
with JIA serum was very similar to levels seen with
healthy control serum and significantly higher than with
JSLE serum (Figure 2A and B). JSLE monocyte-derived
macrophages incubated with 10% JSLE, JIA or control
serum resulted in a marked decreased in the amount of
phagocytosis of apoptotic neutrophils in the cells incu-
bated with 10% JSLE serum compared to controls
(Figure 2C). This again highlights the ability of control
serum to potentially restore phagocytic potential of JSLE
macrophages.
Figure 1 Phagocytosis level of adult healthy macrophages and monocytes in 10% JSLE, JIA and control serum. Adult healthy control
macrophages were incubated in 10% JSLE (n = 8) or control (n = 7) serum and their ability to phagocytose pHrodo stained E. coli was measured by flow
cytometry (A). Macrophages incubated with JSLE serum had significantly decreased phagocytosis ability compared to macrophages incubated with
control serum (p = 0.021). Adult healthy monocytes were incubated with 10% JSLE (n = 10), JIA (n = 8) or control (n = 11) serum and their ability to
phagocytose pHrodo stained E. coli was measured by flow cytometry. There was no significant difference in the amount of phagocytosis between any
of the groups analysed (B). JSLE monocytes were incubated with E coli and either 10% matched JSLE serum, control or JIA serum (C). Levels of E coli
phagocytosis were significantly lower when incubated in matched serum but these levels increased in control or JIA serum (p = 0.002 and p = 0.028
respectively). This graph is a representative experiment of the n = 6 experiments performed (C). Control monocytes were incubated with E coli and
either 10% matched control serum, JSLE or JIA serum. Incubation of healthy control monocytes with 10% JSLE serum caused a significant decrease in
phagocytosis ability in comparison to incubation with control serum (D; p = 0.018). This graph is a representative experiment of the n = 5 experiments
performed. Data are shown as mean ± SEM and the p values were determined by the Mann Whitney U test.
Table 2 Phagocytosis of control and JSLE monocytes in 10% JSLE, JIA and control serum
(A) Control CD14+ cells % Phagocytosis (B) JSLE CD14+ cells % Phagocytosis
Control serum JSLE serum JIA serum Control serum JSLE serum JIA serum
36.7 9.2 34.1 39.5 33.2 21.2
83.6 72.1 81.81 35.8 18.7 62.4
74.72 63.2 69.3 21.6 11.8 20.7
43.73 29.81 42.78 71.1 34.2 64.4
68.3 61.4 76.72 84.81 83.14 93.44
14.31 9.05 12.8
This table presents the percentage phagocytosis of 5 control and 6 JSLE monocytes represented in Figure 1C and D. Control and JSLE monocytes were incubated
with E coli and either 10% control serum, JSLE or JIA serum. The percentage of phagocytosis was lower when incubated with JSLE serum which was increased following
incubation with control or JIA serum.
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Figure 2 Decreased phagocytosis of apoptotic neutrophils in the presence of JSLE serum. Healthy adult control macrophages were
incubated with pHrodo stained apoptotic neutrophils in a 10% JSLE, JIA or healthy paediatric control serum environment (n = 6). Macrophages
not supplemented with serum were used as a base line control and had the lowest phagocytosis index (phagocytosis index = number of macrophages
containing apoptotic material divided by the total number macrophages in the image, averaged across the four areas imaged by confocal microscopy.)
Macrophages in JSLE sera had significantly less phagocytic capacity to engulf apoptotic neutrophils compared to those in the control sera group and JIA
serum; p = 0.03 (A). Panel B shows a series of merged DAPI (blue), pHrodo (red) and Bright field images, from a single representative experiment. Increased
red fluorescence in the control and JIA images indicates increased phagocytosis of apoptotic neutrophils compared to JSLE serum. Panel C represents a
phagocytosis assay using JSLE macrophages incubated with 10% JSLE, JIA or control serum. There is a marked decreased in the amount of red
fluorescence in the macrophages incubated with 10% JSLE serum compared to controls indicating less phagocytosis of apoptotic neutrophils
by these cells, the % of phagocytosis in each serum is shown in D; n = 3.
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Monocytes from JSLE (n = 6), JIA (n = 6) and healthy
control (n = 6) patients were analysed for Mer receptor
levels by flow cytometry (Figure 3A). Mer expression
was significantly decreased on JSLE monocytes comparedto those of healthy controls (p = 0.026). Levels of Mer
were higher on JIA monocytes in comparison to JSLE
monocytes but this difference was not statistically signifi-
cant. There was no significant difference in mRNA expres-
sion of Mer in JSLE monocytes (n = 6) compared to
Figure 3 CD14+ Mer levels and plasma sMer, sTyro and sAXL concentration in JSLE, JIA and control patients. Levels of cell surface Mer
were analysed in JSLE (n = 6), JIA (n = 6) and control (n = 6) patient monocytes (A). Mer was found to be significantly decreased in JSLE monocytes
compared to healthy control monocytes (A; p = 0.026). JSLE (n = 15), JIA (n = 10) and control (n = 15) patient plasma was analysed by ELISA for sMer
concentrations (B). JSLE patients had significantly higher levels of plasma sMer in comparison to JIA and control plasma (B; p = 0.014 and p < 0.001
respectively). In addition JIA patients had significantly increased levels of plasma sMer in comparison to healthy controls (B; p = 0.001). JSLE (n = 30), JIA
(n = 20) and control (n = 30) patient plasma was analysed by ELISA for sTyro3 concentrations (C). JSLE patients had significantly higher plasma levels of
sTyro3 in comparison to JIA and control patients (C; p = 0.004 and p = 0.021 respectively). JSLE (n = 14), JIA (n = 12) and control (n = 14) patient plasma
was analysed by ELISA for sAxl concentrations (D). JSLE patients had significantly higher plasma levels of sAxl in comparison to JIA and control patients
(D; p = 0.0009 and p = 0.0041 respectively). BILAG score is significantly correlated with JSLE plasma sAxl concentration (E; p = 0.0032). Data are shown as
the mean ± SEM and a Mann-Whitney U test was performed to determine significance values.
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rophages (n = 6) and healthy control macrophages (n = 9)
(data not shown).
sMer, sTyro3 and sAxl concentrations are significantly
increased in JSLE plasma
Plasma concentration of sMer was measured in JSLE
(n = 15), JIA (n = 10) and healthy control (n = 15) pa-
tients (Figure 3B). The concentration of sMer was sig-
nificantly increased in JSLE plasma compared to both
JIA and healthy control (p = 0.014 and p < 0.001 respect-
ively); sMer concentration in JIA patients was significantly
increased compared to healthy controls (p = 0.001). JSLE
sMer plasma concentration was inversely correlated to pa-
tient age (r = -0.714, p = 0.003) but not so for JIA or healthy
controls. There was no difference between the sMer con-
centrations of those on corticosteroid treatment (n = 10;
18.32 ± 2.35) and those not (n = 5; 19.89 ± 4.36; p = 0.95)
nor between patients being treated with the immunosup-
pressants (mycophenolate mofetil, Azathioprine) compared
with those who were not (p > 0.05). However, patients re-
ceiving hydroxychloroquine (n = 12) showed significantly
lower levels of plasma sMer compared to patients not re-
ceiving this treatment (n = 3) (p = 0.012) (data not shown).
There was no significant correlation between sMer concen-
tration and markers of JSLE disease activity including the
British Isles Lupus Assessment Group (BILAG) global score
[20]; erythrocyte sedimentation rate (ESR); C reactive pro-
tein (CRP); C3 or C4.
JSLE patients (n = 30) had significantly higher plasma
levels of sTyro3 in comparison to both JIA (n = 20) and
control patients (n = 30;p = 0.004 and p = 0.021 respectively.
Figure 3C). These results did not correlate to any markers
of disease activity or medication analysed (data not shown).
JSLE patients (n = 14) were found to have signifi-
cantly higher plasma levels of sAxl in comparison to
JIA (n = 12) and control patients (n = 14; p = 0.0009 and
p = 0.0041 respectively Figure 3D). JSLE sAxl concen-
tration in plasma was significantly correlated with pa-
tient age (r2 = 0.53, p = 0.046) and BILAG score
(Figure 3E; r2 = 0.35, p = 0.032). sAxl levels did not dif-
fer significantly with patient’s medication.
ADAM17 is present within JSLE monocytes
Due to significantly decreased level of monocyte surface
bound Mer and resultant increased levels of sMer within
JSLE plasma, the level of an enzyme that can be respon-
sible for Mer cleavage, ADAM17 [12], was investigated.
ADAM17 was analysed on the surface of JSLE (n = 6),
control (n = 6) and JIA (n = 6) CD14+ cells by flow cy-
tometry (Figure 4A). However the level of ADAM17 was
not found to be significantly different between the three
patient groups. An ADAM17 activity assay was set up to
elucidate if the ADAM17 enzyme found within ourpatient samples was physiologically active and able to
cleave its substrate. CD14+ cell lysates were isolated
from JSLE (n = 6), JIA (n = 7) and control (n = 7) patients
and incubated with an ADAM17 substrate which emit-
ted a fluorescent signal upon cleavage by ADAM17.
Physiologically active ADAM17 enzyme was present in
all samples analysed. However the level of fluorescence
was not significantly different between JSLE, JIA and
control samples (Figure 4B).
Discussion
This is the first study to date investigating the TAM re-
ceptors and phagocytosis potential of monocytes and
macrophages in JSLE and demonstrated reduced phago-
cytosis, significantly decreased Mer receptor on JSLE
monocytes and significantly increased levels of sMer,
sAxl and sTyro3 in JSLE plasma.
We have previously identified an increase in neutrophil
apoptosis within JSLE patients. Increased apoptotic cell
debris has the potential to lead to prolonged exposure of
auto-antigens to the immune system and therefore to
facilitate the production of antinuclear autoantibodies and
the formation of the characteristic immune complexes
that cause end organ damage. This study is the first to de-
scribe defective phagocytosis in JSLE and shows reduction
in phagocytosis of both bacteria and apoptotic cells in the
presence of JSLE serum. The importance of serum factors
to this fundamental homeostatic process has been
highlighted, with a clear reduction in healthy macro-
phages ability to phagocytise apoptotic neutrophils when
incubated with JSLE serum. The dysregulation between
cell waste production and removal has been identified as
an attractive pathway for therapeutic manipulation [21].
Therefore understanding the mechanisms contributing
to this element of JSLE pathogenesis is vitally important.
The Mer receptor is the main receptor used by mouse
macrophages to phagocytose apoptotic cells [22]. Mice
with a cytoplasmic truncation of Mer, known as merkd,
or lacking the mer receptor (mer-/-) have macrophages
which are deficient in the clearance of apoptotic cells
and also develop progressive lupus-like autoimmunity
with antibodies to chromatin, DNA and IgG [23-25].
Mer-/- mice also have apoptotic cell accumulation within
germinal centres which results in significantly higher
titres of anti-nuclear antibodies (ANA) suggesting that a
delayed clearance of apoptotic cells causes a break of
peripheral B cell tolerance [25]. Knocking out Mer in
mouse macrophages abolishes their ability to phagocyt-
ose apoptotic cells; whereas knocking out either Tyro3
or Axl or both receptors reduced macrophage phagocyt-
osis by half [22]. Therefore whilst macrophages may pri-
marily use Mer receptor for the uptake of apoptotic
cells, both Tryo3 and Axl also play important roles in
macrophage-driven cell clearance. Mer also has an anti-
Figure 4 Protein analysis of ADAM17 enzyme in JSLE, JIA and control monocytes. Levels of ADAM17 were measured by flow cytometry in
JSLE (n = 6), control (n = 6) and JIA (n = 6) CD14 Cells (A). A representative histogram plot of the results is shown (A). CD14 cell lysates were
isolated from JSLE (n = 6), JIA (n = 7) and control (n = 7) patients and measured for ADAM17 activity (B). The presence of ADAM17 causes cleavage of
a substrate which will fluoresce. The level of fluorescence is measured in fluorescent units (FU).
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of LPS-induced acute lung injury enhances inflammatory
responses and induces TNFα and IL-1β production [26].
Significantly higher levels of sMer were detected in
plasma from JSLE patients compared to both JIA and
healthy control patients. This is in keeping with in-
creased levels detected in adult-onset SLE patient
plasma compared to healthy controls, correlating with
disease activity [27,28]. Increased cleavage of the Mer re-
ceptor leading to significantly increased sMer is likely to
have a major impact on the phagocytosis rate within
JSLE. sMer inhibits phagocytosis in vitro [13] and corre-
lates with disease activity in adult-onset SLE [27,28].
Therefore the significantly increased levels of sMer in
JSLE plasma noted here may be a factor causing a sig-
nificant deficit in apoptotic cell clearance found in adult
onset SLE.
ADAM17 is the metalloproteinase enzyme responsible
for cleaving Mer [12]. Previous studies have highlighted
its importance in several disease conditions especially
lung inflammation as prevention of Mer cleavage using
the ADAM17 inhibitor TAPI-0 suppressed acute lung
injury and inflammation [29,30]. Our study demon-
strated all JSLE patient monocytes expressed ADAM17
protein, however there was no significant difference in
expression when comparing JSLE to control and JIA
monocytes. This data is in-keeping with a previous study
demonstrating that ADAM17 was not increased on
CD14+ isolated from adult SLE patients in comparison
to healthy control [31]. The activity assay illustrated that
all of the samples analysed contained physiologically
active ADAM17 however there was no significant differ-
ence in the amount of enzyme activity between JSLE
CD14+ cells and those from JIA or control patients.
Therefore the increase in Mer cleavage leading to signifi-
cantly increased sMer within JSLE plasma may not bedue to increased ADAM17 activity but possibly due to
other cleavage inducers in the plasma such as LPS [13]
or other currently unknown factors. LPS also inhibits
the clearance of neutrophils in vitro by suppressing the
Mer ligand Gas-6 and by inducing TNFα production
which inhibits macrophage phagocytosis in an autocrine
manner [32]. Lupus patients are prone to bacterial infec-
tions and will often have a flare in disease activity upon
infection [33].
As previously mentioned, the other TAM receptors,
Tyro3 and Axl also influence cell phagocytosis and both
receptors have soluble forms which may act as decoy re-
ceptors. JIA plasma sTyro and sAxl levels were observed
to be no different to healthy controls. Plasma sTyro3
and sAxl concentrations were however significantly in-
creased in JSLE patients which is consistent with adult
data [27,28]. Therefore the effect on phagocytosis of
JSLE serum may be reliant on defects in signalling
through the combination of all three TAM receptors ra-
ther than sMER individually. Mer is also highly expressed
on anti-inflammatory M2c macrophages [9] and inhibits
the production of the pro-inflammatory cytokine TNFα
[34]. Consequently, the significantly higher level of sMer
within JIA as well as JSLE plasma may be due to the pro-
inflammatory monocytes inactivating Mer by cleavage
thereby producing high levels of sMer. Cleavage of Mer
could also be causing the JSLE and JIA monocytes to be-
come more activated and increase their secretion of pro-
inflammatory molecules such as TNFα which has been
shown to be present within the serum of JSLE and JIA
patients [35,36].
Analysing the therapeutic regimens of the JSLE patients
indicated a significantly lower level of sMer within JSLE
patients who were being treated with Hydroxychloroquine
(HCQ). Previous studies have demonstrated that the TLR3
ligand poly IC can induce sMer production [12] and SLE-
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HCQ has been shown to inhibit TLR3 function by altering
endosomal acidification [38] therefore patients exposed to
HCQ may have significantly less plasma sMer due to the
drug preventing TLR3 mediated cleavage of Mer. However,
as there were only 3 patients in this subgroup we would
need to investigate further patients to fully understand the
effect of HCQ on sMer. Glucocorticoids increase the
mRNA and surface expression of Mer on cultured mono-
cytes and dendritic cells and enhance their phagocytosis of
apoptotic neutrophils [9,39,40]. However, we did not find
any correlation with the surface level of monocytes Mer ex-
pression in patients being treated with the glucocorticoid
prednisolone. We also did not find any correlation between
the surface level of Mer receptor on monocytes and the
level of sMer within the serum of the same patients within
JSLE, JIA or controls indicating that the amount of receptor
being cleaved is not correlated with the amount of receptor
being produced by the monocyte.
This study also demonstrated that healthy macro-
phages have significantly lower phagocytosis ability to
engulf E. Coli bacteria in the presence of 10% JSLE
serum compared to the same macrophages incubated in
10% control serum. This JSLE serum effect has not pre-
viously been demonstrated in the paediatric age group
and is in keeping with adult-onset disease [15,16]. We
also demonstrated that monocytes from JSLE and
healthy control patients also indicated a JSLE serum ef-
fect on the phagocytosis. Control monocytes had signifi-
cantly decreased phagocytosis when exposed to 10%
JSLE serum in comparison to control serum. Notably,
JSLE neutrophils demonstrate significantly impaired
neutrophil phagocytosis of Salmonella-specific LPS com-
pared to those from healthy controls [41]. Major infec-
tions are common in JSLE patients and are associated
with active disease [42] which our data could suggest
may be due to a decreased ability of JSLE phagocytes to
engulf and remove organisms such as E. Coli.
As already stated we have previously observed in-
creased apoptotic neutrophils in JSLE patients which
could be a potential source of auto-antigens. The de-
creased phagocytosis of apoptotic neutrophils in the
presence of JSLE serum compared to controls observed
in this study provides further evidence that the produc-
tion of auto-antibodies to nuclear material found in SLE
could be due to increased apoptotic neutrophil apoptosis
that aren’t cleared effectively which in part may be due
to an increase in cleavage of the TAM receptors.
Conclusion
In conclusion, this study has demonstrated that phago-
cytosis is impaired in JSLE. Serum factors appear to play
a vital role in inhibiting apoptotic neutrophil clearance
and therefore exposing the immune system to autoantigens.Although the exact mechanisms are yet to be defined, it is
most likely due to a combination of unbalanced elements,
which have the potential to become future therapeutic
targets.
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